支气管哮喘患者不同时期诱导痰及血嗜酸粒细胞水平的观察

目的探讨诱导痰及末梢血嗜酸粒细胞(EOS)比例、诱导痰嗜酸粒细胞阳离子蛋白(ECP)水平在支气管哮喘（简称哮喘）发病不同时期的变化及应用价值。方法检测哮喘发作期40例（发作组）、哮喘缓解期48例（缓解组）、40名正常健康体检者（对照组）的诱导痰及末梢血EOS占白细胞百分比，同时分别测定痰ECP。结果 ①末梢血中EOS比...

Observation of induced sputum and blood eosinophil levels at different times in patients with bronchial asthma

Objective To investigate the changes and value of induced sputum and peripheral blood eosinophils (EOS) ratio, induced sputum eosinophil cationic protein (ECP) levels in the pathogenesis of different periods in patients with bronchial asthma (asthma). Methods The induced sputum and peripheral blood EOS percentage of total white blood cells, and sputum ECP were measured in bronchial asthma in 40 patients (group attack), asthma remission in 48 patients (remission), 40 normal healthy persons (control group). Results ①The proportion of peripheral blood EOS: asthma is higher than the control group (t =3.685 7, P ＜0. 01 ), difference was statistically significant. And asthma is higher than the remission( t =1.836 3, P ＞0.05), remission is higher than the control group( t =1.860 2, P＞0.05), but the difference was not statistically significant. ②Sputum EOS ratio:asthma is higher than the remission and normal control group( t =9.577 6,18.305, P ＜0.01),remission is higher than the control group (t=15.463, P ＜0.01), the differences were very significant statistically significant. ③ Sputum ECP levels:asthma is higher than the remission and normal control group ( t =7.3313, 12.579, P ＜0.01), remission is higher than the control group ( t =8.829 7, P ＜0.01), the differences were very significant statistical significance. Conclusions ①Proportion EOS induced sputum was significantly higher than the proportion of peripheral blood in bronchial asthma in acute exacerbation and remission, induced sputum is better than the proportion of peripheral blood EOS application testing evaluation of the degree of inflammation of asthma. ②ECP levels in induced sputum and sputum EOS ratio is of equal value in the diagnosis of asthma can be used as an indicator of anti-inflammatory treatment of bronchial asthma monitoring and guidance.